The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Novo Nordisk's flagship product is semaglutide. Sold under the names Ozempic and Wegovy, it's one of the leading GLP-1 ...

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

Novo Nordisk will hold its Q2 FY2025 earnings call on Wednesday, before the market opens. The company s having a terrible ...

The popularity of Novo Nordisk's anti-diabetes and weight-loss treatments Ozempic and Wegovy had once made it a darling of ...

Originally created to treat type 2 diabetes, Ozempic has proven effective therapy for a surprising number of ailments and ...